Announced
Completed
Synopsis
SDIC, the largest state-owned investment holding company in China, led a $116m Series A round in Xuanzhu Biopharmaceutical, the innovative drug research and development platform of Sihuan Pharmaceutical. "Xuanzhu Biopharmaceutical is deploying research and development of market-leading innovative drug, and is rapidly promoting clinical research and development and marketing, thus building a strong platform. We are very happy to support Xuanzhu Biopharmaceutical's highly efficient team at this exciting stage. They are using their expertise and capabilities to expand treatment options and benefit Chinese patients," SDIC.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.